Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) recorded EBIT Margin of -440356600.00% in Q4 2023, down 440349780.36 percentage points from -6819.64% a year earlier and down 440350606.62 percentage points from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023) Analysis & Trends
For FY2023, Inhibikase Therapeutics reported EBIT Margin of -7711.98%, up 6974.19 percentage points from FY2022.
- Annual EBIT Margin has a three-year change of -7308.46 percentage points (FY2020 to FY2023).
- Across earlier years, EBIT Margin came in at -14686.17% in FY2022 (-14209.94 pp), -476.23% in FY2021 (-72.71 pp) and -403.52% in FY2020.
- The Q4 2023 figure is the lowest quarterly EBIT Margin in data going back to Q1 2020.
- On a year-over-year basis, EBIT Margin rose in four of the last eight quarters, with an average year-over-year change of -55014269.26 percentage points.
- Peak year-over-year performance for EBIT Margin in the last five years was a gain of 252514.77 percentage points in Q4 2022, against a drop of 440349780.36 percentage points in Q4 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at -5993.38% (Q3 2023), -5328.07% (Q2 2023) and -7307.62% (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | Inhibikase Therapeutics | 357.87 Mn | -227.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -5,993.38% |
| Jun 30, 2023 | -5,328.07% |
| Mar 31, 2023 | -7,307.62% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -61,899.59% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.46% |
| Dec 31, 2021 | -259,334.41% |
| Sep 30, 2021 | -1,361.22% |
| Jun 30, 2021 | -192.83% |
| Mar 31, 2021 | -186.56% |
| Dec 31, 2020 | -704.66% |
| Sep 30, 2020 | -1,761.44% |
| Jun 30, 2020 | -188.50% |
| Mar 31, 2020 | -199.42% |
API Access
Inhibikase Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();